A patient in need of therapeutic and/or prophylactic immunoadhesin chimeras of the invention, e.g., to counter rhinovirus infection and/or symptoms such as occur with colds, can be administered a pharmaceutically effective amount of desired immunoadhesin, preferably as part of a pharmaceutical composition determined, produced, and administered as described above.